ALK and non-small cell lung carcinoma: Crizotinib, an ALK and c-ros oncogene 1 (ROS1) inhibitor, is used to treat ALK-p, advanced, or recurrent NSCLC and has been approved in the United States of America as a treatment option for ROS1-positive metastatic NSCLC [16].